Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - Plaque psoriasis
Tregalizumab (BT-061) - Rheumatoid arthritis
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Annual general meeting approves increase of dividend an...

07.05.2015, News

Biotest AG: Annual general meeting approves increase of dividend and a share split - Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share - Share split with ... [More]

Biotest increases revenues by 16,6%

07.05.2015, News

Biotest increases revenues by 16,6% - Higher Sales in the US - Capacity expansion at headquarter Dreieich in schedule Dreieich, 7 May 2015. The Biotest Group again succeeded to increase ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mo...

24.04.2015, News

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest proves effective protection from Hepatitis B vi...

23.04.2015, News

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The ... [More]

Biotest announces the opening of a plasma collection fa...

13.04.2015, News

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma ... [More]

Biotest increases sales by 16.2%

24.03.2015, News

Biotest increases sales by 16.2% - Earnings before interest and tax (EBIT) at EUR 53.4 million - Expansion project "Biotest Next level" in timeline and budget - Share split with the ... [More]

Biotest AG: Biotest proposes capital increase from capi...

17.03.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital ... [More]

DGAP-AFR: Biotest AG: Announcement according to Article...

10.03.2015, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: ... [More]

Release according to Article 26, Section 1 of the WpHG ...

23.02.2015, PVR

On February 20, 2015, Deka Investment GmbH, Frankfurt am Main, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, ... [More]

Biotest increases revenues significantly by 16.2%

13.02.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases revenues significantly by 16.2% Dreieich, 13. February 2015. According to preliminary and unaudited figures, ... [More]

Biotest AG:

09.02.2015, News

Biotest opens another plasma collection center in the US - Biotest continues strengthening global plasma collection with a second plasma collection center in Jacksonville, North Caroline, ... [More]

Publication according to § 26 paragraph. 1 WpHG with t...

02.02.2015, PVR

Universal-Investment-Gesellschaft mbH, 60486 Frankfurt, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Biotest Presents New Preclinical Data on Tregalizumab (...

18.11.2014, News

Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual Meeting of the American College of Rheumatology in Boston - New preclinical results confirm treatment rationale in ... [More]

Managers of Italian Subsidiary have been charged with ...

17.11.2014, News

Managers of Italian Subsidiary have been charged with illegal price fixing Dreieich, November 17, 2014. In 2010 the public prosecutor of Naples had initiated investigations against numerous ... [More]

Biotest increases sales by 11,5% compared to previous y...

12.11.2014, News

Biotest increases sales by 11,5% compared to previous year - Good interim results of R&D projects Civacir(R) and Tregalizumab (BT-061) - Building permission for capacity expansion in ... [More]

Very good results of Civacir(R) (Hepatitis C Immune Glo...

10.11.2014, News

Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial - Preliminary data presented at the Congress of the American Association for the Study of Liver ... [More]

Biotest receives marketing authorisation for Albiomin 2...

05.11.2014, News

Biotest receives marketing authorisation for Albiomin 20% in China - Marketing approval granted for Albumin in China - The Chinese Pharmamarket is the second largest market for ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialigue with the financial community.